SAN DIEGO, March 8, 2017 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company
focused on developing novel, small molecule drugs across multiple
therapeutic areas, today announced that Amit Munshi, the Company's President and Chief
Executive Officer will present a corporate update at the
27th Annual Oppenheimer Healthcare Conference on
Wednesday, March 22 at 10:55am ET. The conference will take place
March 21-22 at the Westin New York
Grand Central in New York,
NY.
A live audio webcast of the presentation will be available under
the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event.
About Arena Pharmaceuticals
Arena Pharmaceuticals is a
biopharmaceutical company focused on developing novel, small
molecule drugs across multiple therapeutic areas. Arena is focused
on three primary proprietary investigational clinical programs:
etrasimod (APD334) in Phase 2 evaluation for multiple autoimmune
conditions, ralinepag (APD811) in Phase 2 evaluation for pulmonary
arterial hypertension (PAH), and APD371 entering Phase 2 evaluation
for the treatment of pain associated with Crohn's disease. In
addition, Arena has collaborations with the following
pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc.
(commercial stage), Axovant Sciences (Phase 2 candidate), and
Boehringer Ingelheim International GmbH (preclinical
candidate).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about the upcoming presentation; and Arena's focus,
primary programs and collaborations. For such statements, Arena
claims the protection of the Private Securities Litigation Reform
Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to
differ materially from the forward-looking statements include those
disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Contact: Arena Pharmaceuticals, Inc.
Kevin R. Lind, Chief Financial
Officer
klind@arenapharm.com
858.210.3636
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-27th-annual-oppenheimer-healthcare-conference-300420578.html
SOURCE Arena Pharmaceuticals, Inc.